HK1042844A1 - Enhanced vaccines based on chimeric immunoglobuline peptides - Google Patents

Enhanced vaccines based on chimeric immunoglobuline peptides

Info

Publication number
HK1042844A1
HK1042844A1 HK02102312A HK02102312A HK1042844A1 HK 1042844 A1 HK1042844 A1 HK 1042844A1 HK 02102312 A HK02102312 A HK 02102312A HK 02102312 A HK02102312 A HK 02102312A HK 1042844 A1 HK1042844 A1 HK 1042844A1
Authority
HK
Hong Kong
Prior art keywords
immunogenic polypeptides
methods
mammal
ige
nucleic acid
Prior art date
Application number
HK02102312A
Other languages
English (en)
Inventor
Lars T Hellman
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Publication of HK1042844A1 publication Critical patent/HK1042844A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02102312A 1998-11-02 2002-03-26 Enhanced vaccines based on chimeric immunoglobuline peptides HK1042844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
PCT/SE1999/001896 WO2000025722A2 (en) 1998-11-02 1999-10-21 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS

Publications (1)

Publication Number Publication Date
HK1042844A1 true HK1042844A1 (en) 2002-08-30

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102312A HK1042844A1 (en) 1998-11-02 2002-03-26 Enhanced vaccines based on chimeric immunoglobuline peptides

Country Status (18)

Country Link
US (3) US6913749B2 (de)
EP (1) EP1135158B1 (de)
JP (2) JP4205861B2 (de)
KR (1) KR100559918B1 (de)
AT (1) ATE314087T1 (de)
AU (1) AU771889B2 (de)
CA (1) CA2348756A1 (de)
DE (1) DE69929240T2 (de)
DK (1) DK1135158T3 (de)
ES (1) ES2255325T3 (de)
HK (1) HK1042844A1 (de)
HU (1) HUP0105392A3 (de)
IL (1) IL142582A0 (de)
NO (1) NO20012135L (de)
NZ (1) NZ511079A (de)
PL (1) PL348611A1 (de)
PT (1) PT1135158E (de)
WO (1) WO2000025722A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2361635A3 (de) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti-IgE Vakzine
IL154219A0 (en) * 2000-09-06 2003-07-31 Pharmexa As Method for down-regulating ige
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
DE60226853D1 (de) 2001-02-20 2008-07-10 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren
EP2687593A1 (de) * 2001-05-15 2014-01-22 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo-Priming zur Erzeugung zytotoxischer T-Lymphozyten, die für Nicht-Tumorantigene spezifisch sind, zur Behandlung von Autoimmunerkrankung und Allergie
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP1504102A2 (de) * 2002-05-21 2005-02-09 Resistentia Pharmaceuticals AB Chimäre ige-polypeptide und wirtszellen
JP2006510588A (ja) * 2002-09-05 2006-03-30 レジステンシア ファーマシューティカルズ アーベー アレルギーワクチン
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
EP2376108B1 (de) 2008-12-09 2017-02-22 Pfizer Vaccines LLC Ige ch3 peptidimpstoff
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
EP0407392B2 (de) 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
AU645783B2 (en) 1990-01-23 1994-01-27 Tanox Biosystems, Inc. Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor
JPH05508835A (ja) * 1990-05-25 1993-12-09 ペプチド・セラピューティクス・リミテッド 慢性関節リウマチの免疫診断検定法
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
JPH06504438A (ja) * 1990-12-13 1994-05-26 イミュネックス・コーポレーション 白血病抑制因子受容体
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (de) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptid mit eine kreuzreaktivität gegen anti hepatitis b obenflächen antigen antiserum
US6099846A (en) 1992-10-14 2000-08-08 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
JPH09510975A (ja) 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド アレルギー治療用合成ペプチドベース免疫原
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
AU716716B2 (en) * 1995-07-17 2000-03-02 Medivir Uk Ltd Cysteine protease inhibitors for use in treatment of IgE mediated allergic diseases
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
KR100498198B1 (ko) 1996-03-01 2005-09-09 노파르티스 아게 알레르기에 대한 백신접종 및 치료를 위한 펩티드 임뮤노겐
WO1998005684A2 (en) 1996-08-05 1998-02-12 President And Fellows Of Havard College Mhc binding peptide oligomers and methods of use
BR9811462A (pt) 1997-04-15 2000-09-12 Ferring Farma Lab Moléculas de tnfalfa modificadas, dna que codifica tais moléculas de tnfalfa modificadas e vacinas que compreendem tais tnfalfa modificadas e dna.
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
EP1053343A2 (de) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting von genetischen impfstoffvektoren
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2002526419A (ja) 1998-10-05 2002-08-20 ファーメクサ エイ／エス 治療上のワクチン注射のための新規な方法
CN100534529C (zh) 1998-11-30 2009-09-02 希托斯生物技术股份公司 抗原的有序分子呈递，制备及使用的方法
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
TR200103046T2 (tr) 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
IL154219A0 (en) 2000-09-06 2003-07-31 Pharmexa As Method for down-regulating ige
CA2455387A1 (en) 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma

Also Published As

Publication number Publication date
EP1135158A2 (de) 2001-09-26
US20010038843A1 (en) 2001-11-08
US6913749B2 (en) 2005-07-05
WO2000025722A3 (en) 2000-10-12
EP1135158B1 (de) 2005-12-28
WO2000025722A2 (en) 2000-05-11
HUP0105392A2 (hu) 2002-04-29
DK1135158T3 (da) 2006-05-15
KR20010089364A (ko) 2001-10-06
NO20012135L (no) 2001-06-25
ATE314087T1 (de) 2006-01-15
NO20012135D0 (no) 2001-04-30
JP4205861B2 (ja) 2009-01-07
AU771889B2 (en) 2004-04-08
JP2002531064A (ja) 2002-09-24
JP2006068015A (ja) 2006-03-16
PL348611A1 (en) 2002-06-03
JP4188353B2 (ja) 2008-11-26
DE69929240T2 (de) 2006-08-31
PT1135158E (pt) 2006-05-31
HUP0105392A3 (en) 2008-04-28
CA2348756A1 (en) 2000-05-11
US20030031663A1 (en) 2003-02-13
KR100559918B1 (ko) 2006-03-13
IL142582A0 (en) 2002-03-10
US7459158B2 (en) 2008-12-02
DE69929240D1 (de) 2006-02-02
US20040076625A1 (en) 2004-04-22
ES2255325T3 (es) 2006-06-16
AU2008100A (en) 2000-05-22
NZ511079A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
HK1042844A1 (en) Enhanced vaccines based on chimeric immunoglobuline peptides
NO20210499A1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
SI0970126T1 (en) Novel method for the production of antihuman antigen receptors and uses thereof
EP0939653A4 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
EP1158004A3 (de) Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon
GR3034349T3 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
HUP9702359A2 (hu) Monoklonális antitest, eljárás monoklonális antitest előállítására, valamint a monoklonális antitestet tartalmazó gyógyászati készítmény és diagnosztikai reagens
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
NO20052714D0 (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
EP1621209A3 (de) Vakzinen die auf Domänen von chimären Immunoglobulin E Peptide basieren
Skea et al. Adhesion-mediated enhancement of the adjuvant activity of alum
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
Lou et al. Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine
MY171238A (en) Anti-tnf antibodies, compositions, methods and uses
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101021